ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)
Entera Bio Ltd. presented encouraging Phase 1 clinical data at ENDO 2026 demonstrating that their single tablet oral anabolic therapy, EB613, achieved pharmacokinetic and pharmacodynamic profiles comparable to the injectable standard treatment Forteo4. EB613 was well-tolerated with a favorable safety profile and was preferred by study participants…